CCR5 and p53 codon 72 gene polymorphisms: Implications in breast cancer development

International Journal of Molecular Medicine

Volumn 23, Issue 3, 2009, Pages 429-435

  Aoki, Mateus Nobrega ^a   Do Amaral Herrera, Ana Cristina Da Silva ^a   Amarante, Marla Karine ^a   Do Val Carneiro, Juliana Laino ^a   Fungaro, Maria Helena Pelegrinelli ^a   Watanabe, Maria Angelica Ehara ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Breast cancer; CCR5; p53

Indexed keywords

CHEMOKINE RECEPTOR CCR5; PROTEIN P53; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRAZIL; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER STAGING; CODON; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ALLELE; BREAST TUMOR; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; BRAZIL; BREAST NEOPLASMS; CODON; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 64249101165     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000148     Document Type: Article

References (26)

1. Sherr CJ: Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663-673, 2006.
2. Harris SL and Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908, 2005.
3. Vousden KH and Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594-604, 2002.
4. Matlashewski GJ, Tuck S, Pim D, Lamb P, Schneider J and Crawford LV: Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol 7: 961-963, 1987.
5. Siddique MM, Balram C, Fiszer-Maliszewska L, Aggarwal A, Tan A, Tan P, Soo KC and Sabapathy K: Evidence for selective expression of the p53 codon 72 polymorphs: Implications in cancer development. Cancer Epidemiol Biomarkers Prev 14: 2245-2252, 2005.
6. Mañes S, Mira E, Colomer R, Montero S, Real LM, Gómez-Moutón C, Jiménez-Baranda S, Garzón A, Lacalle RA, Harshman K, Ruíz A and Martinez C: CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 198: 1381-1389, 2003.
7. Taub D, Turcovski S, Key M, Longo D and Murphy W: Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. J Immunol 156: 2095-2103, 1996.
8. Martinson JJ, Chapman NH, Rees DC, Liu YT and Clegg JB: Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 16: 100-103, 1997.
9. Yang X, Ahmad T and Gogus F: Analysis of the CC chemokine receptor (CCR5) Delta32 polymorphism in Behcet's disease, Eur J Immunogenet 31: 11-14, 2004.
10. Oliveira KB, Reiche EMV, Morimoto HK, Fungaro MHP, Estevao D, Pontello R, Nasser TF and Watanabe MAE: Analysis of the CC chemokine receptor 5 delta32 polymorphism in a Brazilian population with cutaneous leishmaniasis. J Cutan Pathol 34: 27-32, 2007.
11. Kaimen-Maciel DR, Reiche EV, Souza DGB, Comini ERF, Bobroff F, Morimoto HK, Watanabe MAE, Oliveira JC, Matsuo T, Lopes J and Donadi EA: CCR5-Δ32 genetic polymorphism associated with benign clinical course and magnetic resonance imaging findings in Brazilian patients with multiple sclerosis. Int J Mol Med 20: 337-344, 2007.
12. Kirby LT: DNA fingerprinting: an introduction. Stocton Press, New York, NY, 1990.
13. Papadakis ED, Soulitzis N and Spandidos DA: Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 87: 1013-1018, 2002.
14. Lima JM, Serafim PVP, Silva IDCG and Forones NM: Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer. Arq Gastroenterol 43: 8-13, 2006.
15. Instituto Brasileiro de Geografia e Estatística - IBGE: Síntese de Indicadores Sociais, 2006.
16. Kirkwood TB and Austad SN: Why do we age? Nature 408: 233-238, 2000.
17. Hasty P, Campisi J, Hoeijmakers J, van Steeg H and Vijg J: Ageing and genome maintenance: lessons from the mouse? Science 299: 1355-1359, 2003.
18. Muxel SM, Borelli SD, Amarante MK, Voltarelli JC, Aoki MN, Oliveira CEC and Watanabe MAE: Association study of CCR5 delta 32 polymorphism among the HLA-DRB1 Caucasian population in Northern Paraná, Brazil, J Clin Lab Anal 22: 229-233, 2008.
19. Papadakis EN, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 3: 389-392, 2000.
20. Weston A and Godbold JH: Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ Health Perspect 105: 919-926, 1997.
21. Pezeshki A, Sari-Aslani F, Ghaderi A and Doroudchi M: p53 codon 72 polymorphism in basal cell carcinoma of the skin. Pathol Oncol Res 12: 29-33, 2006.
22. Nanki T and Lipsky PE: Stimulation of T-cell activation by CXCL12/SDF-1 involves a G-protein mediated signaling pathway. Cell Immunol 214: 145-154, 2001.
23. Panzer U, Schneider A, Steinmetz OM, et al: The chemokine receptor 5 Delta32 mutation is associated with increased renal survival in patients with IgA nephropathy. Kidney Int 67: 75-81, 2005.
24. Loetscher P, Uguccioni M, Bordoli L, et al: CCR5 is characteristic of Th1 lymphocytes. Nature 391: 344-345, 1998.
25. Sidoti A, D'Angelo R, Rinaldi C, et al: Distribution of the mutated delta32 allele of the CCR5 gene in a Sicilian population. Int J Immunogenet 32: 193-198, 2005.
26. van Deventer HW, O'Connor W Jr, Brickey WJ, Aris RM, Ting JPY and Serody JS: C-C Chemokine receptor 5 on stromal cells promotes pulmonary metastasis. Cancer Res 65: 3374-3379, 2005.